Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-01
- Development stage
- Phase 2
- Lead developer
- Seed Health
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
DS-01 is a multi-strain synbiotic developed by Seed Health, designed to support gastrointestinal and systemic health. It contains a proprietary blend of 24 probiotic strains across 12 species, including *Lactobacillus* and *Bifidobacterium*, paired with a non-fermentable prebiotic (punicalagins) derived from Indian pomegranate. The product utilizes a specialized capsule-in-capsule delivery system (ViaCap) to ensure the live microorganisms survive transit through the stomach and reach the colon. DS-01 is being investigated in clinical trials for its impact on fecal metagenomic stability, gut barrier integrity, and symptoms of irritable bowel syndrome (IBS), particularly the constipation-predominant (IBS-C) and mixed (IBS-M) subtypes.
- Brand names
- Seed DS-01 Daily Synbiotic
- Other names
- Seed Daily SynbioticDS-01 SynbioticDS01 SynbioticDS 01 Synbiotic
Beyond the preview
Go deeper on DS-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-01.